The present study aimed to examine whether the APOE ε4 allele, associated with dementia with Lewy bodies (DBL), and possibly with dementia in Parkinson’s disease (PD), is also associated with idiopathic rapid eye movement sleep behavior disorder (RBD). Two single nucleotide polymorphisms, rs429358 and rs7412, were genotyped in RBD patients (n = 480) and in controls (n = 823). APOE ε4 allele frequency was 0.14 among RBD patients and 0.13 among controls (OR = 1.11, 95% CI: 0.88–1.40, p = 0.41). APOE ε4 allele...
1. Introduction

Rapid eye movement (REM) sleep behavior disorder (RBD) is currently the strongest clinical prodromal feature preceding the development of an overt synucleinopathy, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) (Iranzo et al., 2014). One of the strongest genetic factors associated with DLB is the APOE ε4 allele (Pickering-Brown et al., 1994), and PD patients who carry this allele may be at increased risk for developing dementia. Since both RBD and the APOE ε4 allele are possibly associated with DLB, and with dementia in PD patients, we aimed to examine whether the APOE ε4 allele is associated with RBD and conversion to DLB. See Supplementary Material for detailed introduction and full list of references.

2. Methods

The study population included idiopathic RBD patients (n = 480) and controls (n = 823) of European ancestry. RBD patients were diagnosed using clinical interview and polysomnography according to the International Classification of Sleep Disorders, Version 2 criteria. The control group was composed of 253 elderly controls (age 59.5 ± 9.8 years, matched to the available age at onset (AAO) of RBD, n = 307, age 59.2 ± 11.5), 510 young controls (age 34.0 ± 6.5 years), and additional 60 controls with no available data on age. All control groups had nearly identical frequencies of the APOE ε4 allele (0.13, 0.13, and 0.14, respectively), which allowed us to analyze all controls combined. All individuals signed informed consent forms at enrollment, and the study protocols were approved by the respective institutional review boards. DNA was extracted using a standard salting-out protocol. Two single nucleotide polymorphisms, rs429358 and rs7412, were genotyped using TaqMan single nucleotide polymorphism genotyping assays. Genotypes were called using the QuantStudio 7 Flex Real-Time PCR System and Software (V 1.0). Goodness of fit test with 1 degree of freedom was applied to look for deviation from the Hardy–Weinberg equilibrium among the controls. Differences in APOE allele or carriage frequencies were analyzed using the Fisher’s exact test, and differences in continuous variables were analyzed using t test. A logistic regression model with age and sex as covariates was also applied. All statistical analysis was done using SPSS statistics V.23 (IBM Inc). Detailed methods can be found in the Supplementary Material.

3. Results

The allele frequency of APOE ε4 was 0.14 among RBD patients and 0.13 among controls (OR = 1.11, 95% CI: 0.88–1.40, p = 0.41). Overall, 25.8% of RBD patients carried at least 1 APOE ε4 compared to 23.0% among controls (p = 0.25, Fisher’s exact test), and there were more homozygous carriers of the APOE ε4 allele among controls (3.2%) as compared to RBD patients (2.7%). Logistic regression model adjusted for age and sex also demonstrated lack of association between APOE ε4 allele carriage and risk for RBD (OR = 1.25, 95% CI: 0.87–1.79, p = 0.23). There was no difference in AAO when comparing carriers (n = 88) and noncarriers (n = 219) of the APOE ε4 allele (59.1 ± 8.4 vs. 59.3 ± 12.6 years, respectively, p = 0.92, t test). A total of 140 RBD patients (29.2%) were reported to have converted to either PD (n = 98, 70% of the converters), dementia/DLB (n = 28, 20%), or MSA (n = 14, 10%) The carrier frequencies of one or more APOE ε4 in these groups were similar: 23.5%, 25.0%, and 28.6%, respectively (p = 0.91), and the allele frequencies were 0.12, 0.14, and 0.14 (p = 1.0). The APOE ε4 allele frequency among those that did not convert was slightly higher, 0.15 (Table 1), with a total of 26.5% carriers of at least one APOE ε4 allele, compared to 24.3% among those who converted (p = 0.65). More detailed results can be found in the Supplementary Material.

4. Discussion

Although RBD is a strong risk factor for developing DLB and although DLB was reported to be associated with the APOE ε4 allele, our results demonstrate lack of association between the APOE ε4 allele and RBD or its AAO. These and previous results further suggest that RBD may have a distinct genetic background; it is associated with GBA mutations (Gan-Or et al., 2015b), but unlike PD, it is not associated with LRRK2 mutations (Fernandez-Santiago et al., 2016), and unlike DLB, it is not associated with the APOE ε4 allele. Thus far, GBA, SCARB2, and potentially SNCA (Gan-Or et al., 2015a) overlap between RBD, PD, and DLB (Supplementary Material). Whether RBD has additional, unique genetic factors that were not identified in PD or DLB cohorts is still to be determined. Our present study identified similar frequencies of APOE ε4 allele in those who progressed to PD, DLB, and MSA, suggesting that APOE alleles do not affect the type of subsequent synucleinopathy. Our study has some limitations, and a more detailed discussion including full list of references can be found in the Supplementary Material. Our results support a distinct genetic background for RBD-associated

Table 1

<table>
<thead>
<tr>
<th>APOE haplotypes in individuals with RBD and controls</th>
<th>ε2ε2, n, (%)</th>
<th>ε2ε3, n, (%)</th>
<th>ε3ε3, n, (%)</th>
<th>ε2ε4, n, (%)</th>
<th>ε3ε4, n, (%)</th>
<th>ε4ε4, n, (%)</th>
<th>Total carriers of ε4, n (%)</th>
<th>ε4 allele frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>RBD patients, n = 480</td>
<td>4 (0.8)</td>
<td>51 (10.6)</td>
<td>301 (62.7)</td>
<td>4 (0.8)</td>
<td>107 (22.3)</td>
<td>13 (2.7)</td>
<td>124 (25.8)</td>
<td>0.14</td>
</tr>
<tr>
<td>RBD converted to synucleinopathy, n = 140</td>
<td>3 (2.1)</td>
<td>12 (8.6)</td>
<td>91 (65.0)</td>
<td>1 (0.7)</td>
<td>32 (22.9)</td>
<td>1 (0.7)</td>
<td>34 (24.3)</td>
<td>0.13</td>
</tr>
<tr>
<td>RBD not converted to synucleinopathy, n = 340</td>
<td>1 (0.3)</td>
<td>39 (11.5)</td>
<td>210 (61.8)</td>
<td>3 (0.9)</td>
<td>75 (22.1)</td>
<td>12 (3.5)</td>
<td>90 (26.5)</td>
<td>0.15</td>
</tr>
<tr>
<td>Controls, n = 823</td>
<td>5 (0.6)</td>
<td>111 (13.5)</td>
<td>518 (62.9)</td>
<td>14 (1.7)</td>
<td>149 (18.1)</td>
<td>26 (3.2)</td>
<td>189 (23.0)</td>
<td>0.13</td>
</tr>
</tbody>
</table>

Key: DLB, dementia with Lewy bodies; MSA, multiple system atrophy; n, number; PD, Parkinson’s disease; RBD, REM sleep behavior disorder.
neurodegeneration, probably suggesting a specific genetic association with synucleinopathy rather than tauopathy/amyloidopathy.

**Disclosure statement**

Dr. Gan-Or received consultation fees from Sanofi/Genzyme. Dr. Montplaisir received speaking honoraria from Valeant Pharmaceutical and Otsuka Pharmaceutical, serves on the advisory boards of Sanofi–Aventis, Servier, Merck, Jazz Pharma, Valeant Pharma, Impax Laboratories, Glaxo-SmithKline, UCB Canada, and received consultancy fees from Otsuka Pharma and Valeant Pharma. Dr. Ross and Dr. Poirier report no conflict of interests. Dr. Warby received honoraria from Pfizer, Bristol-Myers Squibb, SmithKline Beecham, and Eli Lilly. Dr. Arnulf received speaker honoraria from UCB Pharma. Dr. Strong reports no conflicts of interests. Dr. Dauvilliers is on the advisory board and received travel and consultancy fees from UCB Pharma, bioprojet, and Jazz Pharma. Dr. Leblond and Dr. Hu report no conflict of interests. Dr. Högl received speaker honoraria from UCB, Otsuka, Abbiev, Lundbeck, Lilly, and Mundipharma. Serving on advisory boards or consulting for Mundipharma, Axovant. Received travel support from Habel Medizintechnik, Vivisol. Dr. Stefani reports no conflict of interests. Dr. Christelle Charley Monaca received fees for serving on an advisory board of UCB Pharma, lecture fees from UCB Pharma, Orkyn. Dr. De Cock received funding from Orkyn, LVL medical, Teva, and UCB. Dr. Boivin and Dr. Ferini-Strambi report no conflicts of interests. Dr. Piazza served on the advisory board of UCB Pharma, jazz pharmaceuticals, and Bioprojet. Dr. Antelmi reports no conflict of interests. Dr. Young received honoraria for speakers’ bureaus by Sanofi Genzyme, Biomarin, UCB pharmaceuticals, Medice, ResMed, and Heinen and Löwenstein. Member of advisory boards for Sanofi Genzyme, Biomarin, Vanda and Medice. Dr. Heidbreder received travel support Habel Medizintechnik, received lecture honoraria from UCB, Heinen und Löwenstein. Dr. Barber and Dr. Evetts report no conflict of interests. Dr. Rolinski and Dr. Dion report no conflict of interests. Dr. Desautels received speaker honoraria from UCB and Paladin labs.

**Acknowledgements**

The authors would like to thank all the participants in the study. This work was funded by a grant to ZGO from the Michael J. Fox Foundation for Parkinson’s research. Part of this work was funded by an interface grant to IA from INSERM. The French DNA collection was promoted by the Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil (ADOREPS), project PARAGEN, PI Isabelle Arnulf. The Oxford Discovery cohort was funded by the Monument Trust Discovery Award from Parkinson’s UK and supported by the National Institute for Health Research, Oxford Biomedical Research Centre based at Oxford University Hospitals, NHS Trust, , University Oxford, and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). Part of this work was funded by the Weston Brain Institute (grants to JYM and JP) and the J.L. Levesque Foundation (grant to JP). Part of this work was funded by grants to PY from the Lowensteinsteinstiftung and the German Ministry of Education and Science (BMBF). JFG holds a Canada Research Chair on Cognitive Decline in Pathological Aging. GAR holds a Canada Research Chair in Genetics of the Nervous System and the Wilder Penfield Chair in Neurosciences. The authors thank Cynthia Bourassa, Sandra Laurent, Helene Catoire, Pascale Hince, and Vessela Zabaraneva for their assistance. AD received research grants from Novartis pharma, Jazz Pharmaceuticals, Biron soins du sommeil. JYM reports grants from Merck, GlaxoSmithKline. BH received grant from UCB.

**Appendix A. Supplementary data**


**References**


